IGC Pharma (IGC) Common Equity (2011 - 2026)
IGC Pharma (IGC) posted quarterly Common Equity of $6.1 million for Q1 2026, down 3.3% year-over-year from $6.3 million in Q1 2025, and down 17.54% quarter-over-quarter from $7.4 million in Q4 2025.
IGC Pharma (IGC) Common Equity (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Common Equity for 16 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 3.3% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 3.3% YoY), while the FY2026 annual figure was $6.1 million, down 3.3% from the prior year.
- Common Equity eased to $6.1 million in Q1 2026 per IGC's latest filing, from $7.4 million in the prior quarter.
- Across five years, Common Equity topped out at $23.9 million in Q1 2022 and bottomed at $6.1 million in Q2 2025.
- Historically, Common Equity has averaged $11.7 million across 5 years, with a median of $8.1 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity slumped 50.9% — and 2025, when it gained 18.6%.
- IGC Pharma's Common Equity stood at $18.3 million in 2022, then sank by 50.58% to $9.1 million in 2023, then sank by 30.86% to $6.3 million in 2024, then gained by 18.6% to $7.4 million in 2025, then dropped by 17.54% to $6.1 million in 2026.
- Business Quant data shows IGC's Common Equity at $6.1 million in Q1 2026, $7.4 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | 6.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | 7.42 Mn |
| Sep 30, 2025 | 8.09 Mn |
| Jun 30, 2025 | 6.08 Mn |
| Mar 31, 2025 | 6.33 Mn |
| Dec 31, 2024 | 6.26 Mn |
| Sep 30, 2024 | 7.38 Mn |
| Jun 30, 2024 | 7.88 Mn |
| Mar 31, 2024 | 7.32 Mn |
| Dec 31, 2023 | 9.05 Mn |
| Sep 30, 2023 | 14.10 Mn |
| Jun 30, 2023 | 13.20 Mn |
| Mar 31, 2023 | 14.91 Mn |
| Dec 31, 2022 | 18.32 Mn |
| Sep 30, 2022 | 20.14 Mn |
| Jun 30, 2022 | 22.04 Mn |
| Mar 31, 2022 | 23.89 Mn |
| Dec 31, 2021 | 29.48 Mn |
| Sep 30, 2021 | 31.26 Mn |
| Jun 30, 2021 | 31.74 Mn |